Mark X Du

Summary

Publications

  1. ncbi Identification of novel small-molecule inhibitors for human transketolase by high-throughput screening with fluorescent intensity (FLINT) assay
    Mark X Du
    S BIO, Singapore
    J Biomol Screen 9:427-33. 2004
  2. ncbi Comparative characterization of two DEAD-box RNA helicases in superfamily II: human translation-initiation factor 4A and hepatitis C virus non-structural protein 3 (NS3) helicase
    Mark X Du
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Biochem J 363:147-55. 2002

Collaborators

Detail Information

Publications2

  1. ncbi Identification of novel small-molecule inhibitors for human transketolase by high-throughput screening with fluorescent intensity (FLINT) assay
    Mark X Du
    S BIO, Singapore
    J Biomol Screen 9:427-33. 2004
    ..Identification of these active scaffolds represents a good starting point for development of drugs specifically targeting TK and the nonoxidative PPP for cancer therapy...
  2. ncbi Comparative characterization of two DEAD-box RNA helicases in superfamily II: human translation-initiation factor 4A and hepatitis C virus non-structural protein 3 (NS3) helicase
    Mark X Du
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Biochem J 363:147-55. 2002
    ..The observed differences in their substrate specificity may prove to be useful in designing specific inhibitors targeting HCV NS3 helicase but not human eIF4A...